IXP
VX20-147-006
Phase 1 small_molecule completed
Quick answer
IXP for Focal Segmental Glomerulosclerosis (FSGS) is a Phase 1 program (small_molecule) at VERTEX PHARMACEUTICALS INC / MA with 1 ClinicalTrials.gov record(s).
Program details
- Company
- VERTEX PHARMACEUTICALS INC / MA
- Indication
- Focal Segmental Glomerulosclerosis (FSGS)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed